AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25194996 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure of buccal mucosal graft harvest site
Number of subjects: 34
Study 25194996 — intervention group
Group type: COMPARATOR
Intervention: Nonclosure of buccal mucosal graft harvest site
Number of subjects: 34
Study 22265989 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-free toothpaste (BT)
Number of subjects: 36
Study 22265989 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste (BFT)
Number of subjects: 36
Study 22265989 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with deionised water (BW)
Number of subjects: 36
Study 22265989 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion in fluoride-free toothpaste (IFT)
Number of subjects: 36
Study 22265989 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion in fluoride toothpaste (IT)
Number of subjects: 36
Study 22265989 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion in deionised water (IW)
Number of subjects: 36
Study 22265989 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with fluoride toothpaste (BT)
Number of subjects: 36
Study 22265989 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with fluoride-free toothpaste (BFT)
Number of subjects: 36
Study 20226618 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES) implantation
Number of subjects: 450
Study 20226618 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES) implantation
Number of subjects: 450
Study 17663046 — intervention group
Group type: EXPERIMENTAL
Intervention: Millimeter-range electromagnetic radiation therapy
Number of subjects: 152
Study 17663046 — intervention group
Group type: EXPERIMENTAL
Intervention: Millimeter-range noise electromagnetic radiation
Number of subjects: 152
Study 17966001 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubinus Flanged Anti‐Luxation cup (FAL)
Number of subjects: 53
Study 17966001 — intervention group
Group type: COMPARATOR
Intervention: Lubinus Standard Eccentric cup (Standard)
Number of subjects: 53
Study 17966001 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (FAL and Standard)
Number of subjects: 53
Study 14682195 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive measures including physical exercise and protein energy intake
Number of subjects: 102
Study 14682195 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving preventive measures)
Number of subjects: 102
Study 11039135 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping of 45 s
Number of subjects: 40
Study 11039135 — intervention group
Group type: COMPARATOR
Intervention: Delayed cord clamping of 20 s
Number of subjects: 40
Study 9177976 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (0.05 mg/kg/day)
Number of subjects: 19
Study 9177976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyloestradiol (40 ng/kg/day)
Number of subjects: 19
Study 9177976 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low dose oxandrolone and oestrogen
Number of subjects: 19
Study 1609044 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine cortex phosphatidylserine (BC‐PS; 100 mg t.i.d.)
Number of subjects: 51
Study 1609044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 3907394 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release terbutaline sulphate 5 mg twice a day
Number of subjects: 30
Study 3907394 — intervention group
Group type: COMPARATOR
Intervention: Ordinary tablets 2.5 mg three times a day
Number of subjects: 30
Study 31774980 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-clinical cohort scores for the IPAS subdomain of teamwork, roles, and responsibilities
Number of subjects: 865
Study 31774980 — intervention group
Group type: COMPARATOR
Intervention: Baseline and post-didactic cohort scores
Number of subjects: 865
Study 28369652 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding
Number of subjects: 62
Study 28369652 — intervention group
Group type: COMPARATOR
Intervention: Late feeding
Number of subjects: 62
Study 28369652 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding (very preterm)
Number of subjects: 62
Study 28369652 — intervention group
Group type: COMPARATOR
Intervention: Late feeding (very preterm)
Number of subjects: 62
Study 27015546 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone (5 mg)
Number of subjects: 150
Study 27015546 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexamethasone (5 mg)
Number of subjects: 150
Study 24693959 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus interlaminar epidural steroid injection
Number of subjects: 14
Study 24693959 — intervention group
Group type: COMPARATOR
Intervention: Interlaminar epidural steroid injection
Number of subjects: 14
Study 22861076 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine patches (700 mg)
Number of subjects: 40
Study 22861076 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 40
Study 20433740 — intervention group
Group type: EXPERIMENTAL
Intervention: Early developmental intervention plus health and safety counseling
Number of subjects: 431
Study 20433740 — intervention group
Group type: COMPARATOR
Intervention: Health and safety counseling only (Control)
Number of subjects: 431
Study 18568553 — intervention group
Group type: EXPERIMENTAL
Intervention: 5M CRT monitors
Number of subjects: 100
Study 18568553 — intervention group
Group type: COMPARATOR
Intervention: 3M LCD monitors
Number of subjects: 100
Study 16005120 — intervention group
Group type: EXPERIMENTAL
Intervention: Virosomal influenza vaccine
Number of subjects: 0
Study 16005120 — intervention group
Group type: COMPARATOR
Intervention: Conventional subunit vaccine
Number of subjects: 0
Study 12426518 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa administered once weekly (n = 17)
Number of subjects: 47
Study 12426518 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa administered 3 times weekly (n = 15)
Number of subjects: 47
Study 12426518 — intervention group
Group type: COMPARATOR
Intervention: Epoetin administered 3 times weekly (n = 15)
Number of subjects: 47
Study 12426518 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (once and three times weekly) and Epoetin (three times weekly)
Number of subjects: 47
Study 12426518 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa and Epoetin
Number of subjects: 47
Study 10233652 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart as an aide memoire for topical medications
Number of subjects: 100
Study 10233652 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chart used)
Number of subjects: 100
Study 7805919 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) injection (1 mg/kg)
Number of subjects: 40
Study 7805919 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic salpingotomy
Number of subjects: 40
Study 1655177 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 5 mg daily
Number of subjects: 55
Study 1655177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 1655177 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal variation
Number of subjects: 55
Study 6336951 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 1.5 g three times daily for 5 days starting on the first day of menstruation
Number of subjects: 19
Study 6336951 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (DS) 50 mg three times on the first day followed by 25 mg three times daily for 4 days
Number of subjects: 19
Study 6336951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30612372 — intervention group
Group type: EXPERIMENTAL
Intervention: NAHSIT 93-96 (N=821)
Number of subjects: 1601
Study 30612372 — intervention group
Group type: EXPERIMENTAL
Intervention: NAHSIT 05-08 (N=780)
Number of subjects: 1601
Study 30612372 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with alcohol consumption, betel quid chewing, or cigarette smoking
Number of subjects: 1601
Study 29539585 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise (70% of VO2max)
Number of subjects: 77
Study 29539585 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity aerobic exercise (30% of VO2max)
Number of subjects: 77
Study 29539585 — intervention group
Group type: COMPARATOR
Intervention: Exposure-based Cognitive Behavioral Therapy (eb-CBT)
Number of subjects: 77
Study 27283792 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg subcutaneous (s.c.) relamorelin
Number of subjects: 16
Study 27283792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 24284470 — intervention group
Group type: EXPERIMENTAL
Intervention: Oculomotor training (OMT)
Number of subjects: 12
Study 24284470 — intervention group
Group type: COMPARATOR
Intervention: Sham training (ST)
Number of subjects: 12
Study 22262484 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion during high sodium intake (HS; 300 mmol sodium/day)
Number of subjects: 0
Study 22262484 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion during low sodium intake (LS; 30 mmol sodium/day)
Number of subjects: 0
Study 22262484 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion
Number of subjects: 0
Study 22262484 — intervention group
Group type: COMPARATOR
Intervention: Baseline conditions
Number of subjects: 0
Study 19075273 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (first cycle)
Number of subjects: 104
Study 19075273 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (second cycle)
Number of subjects: 104
Study 19075273 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SUV < 3.0
Number of subjects: 104
Study 19075273 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold of 45% decrease in SUV
Number of subjects: 104
Study 17524265 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg daily
Number of subjects: 332
Study 17524265 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine 100 mg daily
Number of subjects: 332
Study 17524265 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine
Number of subjects: 332
Study 17524265 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine and Lamivudine
Number of subjects: 332
Study 15948744 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine ER 4 mg once daily
Number of subjects: 293
Study 15948744 — intervention group
Group type: COMPARATOR
Intervention: oxybutynin 3 mg three times daily
Number of subjects: 293
Study 15948744 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 293
Study 12077732 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet (8% carbohydrate) for 6 weeks
Number of subjects: 12
Study 12077732 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal diet)
Number of subjects: 12
Study 9462396 — intervention group
Group type: EXPERIMENTAL
Intervention: Marsupialization (MS group)
Number of subjects: 103
Study 9462396 — intervention group
Group type: COMPARATOR
Intervention: Leaving wounds open (LO group)
Number of subjects: 103
Study 7666089 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI 5‐FU 300 mg/m2/d plus IFN 5 MU subcutaneously three times weekly
Number of subjects: 160
Study 7666089 — intervention group
Group type: COMPARATOR
Intervention: PVI 5‐FU alone
Number of subjects: 160
Study 7666089 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI 5‐FU plus IFN
Number of subjects: 160
Study 2759973 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine-caffeine mixture (1 mg/kg ephedrine, 2.5 mg/kg caffeine)
Number of subjects: 9
Study 2759973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 778656 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine
Number of subjects: 20
Study 778656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31612188 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg rectal diclofenac
Number of subjects: 100
Study 31612188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31612188 — intervention group
Group type: COMPARATOR
Intervention: 50 mg oral diclofenac
Number of subjects: 100
Study 31612188 — intervention group
Group type: COMPARATOR
Intervention: 75 mg/3 ml intramuscular diclofenac sodium
Number of subjects: 100
Study 31612188 — intervention group
Group type: COMPARATOR
Intervention: 75 mg/3 ml intravenous diclofenac
Number of subjects: 100
Study 28558714 — intervention group
Group type: EXPERIMENTAL
Intervention: ProF-Cog intervention including falls risk assessment, tailored intervention (dementia care mapping, comprehensive geriatric assessment, occupational therapy, twice-weekly exercise for 6 months)
Number of subjects: 191
Study 28558714 — intervention group
Group type: COMPARATOR
Intervention: Usual care without falls risk assessment
Number of subjects: 191
Study 28558714 — intervention group
Group type: EXPERIMENTAL
Intervention: ProF-Cog intervention
Number of subjects: 191
Study 28558714 — intervention group
Group type: COMPARATOR
Intervention: ProF-Cog intervention and usual care
Number of subjects: 191
Study 26075486 — intervention group
Group type: COMPARATOR
Intervention: Monetary reinforcement and response cost
Number of subjects: 40
Study 26075486 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (MPH)
Number of subjects: 40
Study 26075486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26075486 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effect of reinforcement and MPH
Number of subjects: 40
Study 23485054 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 0
Study 23485054 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 21439546 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 0.3 μg/kg
Number of subjects: 43
Study 21439546 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 43
Study 19436663 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (5 mg) once daily
Number of subjects: 320
Study 19436663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 16393880 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA supplementation
Number of subjects: 0
Study 16195088 — intervention group
Group type: EXPERIMENTAL
Intervention: Real left prefrontal high‐frequency rTMS (20 trains of 10 s, 60‐s interval, 10 Hz, 90% of motor threshold)
Number of subjects: 15
Study 16195088 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 15
Study 15982126 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrelevant spatial mismatch
Number of subjects: 0
Study 15982126 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrelevant functional mismatch
Number of subjects: 0
Study 15982126 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional relation context
Number of subjects: 0
Study 15982126 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial relation context
Number of subjects: 0
Study 10328277 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal diazepam (DZP) gel
Number of subjects: 133
Study 10328277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 7743305 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 41
Study 7743305 — intervention group
Group type: COMPARATOR
Intervention: Oesophageal transection
Number of subjects: 41
Study 2147612 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 50
Study 2147612 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 50
Study 2147612 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 50
Study 2147612 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 50
Study 2147612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7001487 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg protacine 3-times daily for 21 days
Number of subjects: 30
Study 7001487 — intervention group
Group type: COMPARATOR
Intervention: 200 mg oxyphenbutazone 3-times daily for 21 days
Number of subjects: 30
Study 7001487 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg protacine
Number of subjects: 30
Study 7001487 — intervention group
Group type: COMPARATOR
Intervention: 200 mg oxyphenbutazone
Number of subjects: 30
Study 31809955 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide (0.1 mg/kg PO q 12 h)
Number of subjects: 6
Study 31809955 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (2.0 mg/kg PO q 12 h)
Number of subjects: 6
Study 31809955 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic groups (Torsemide and Furosemide)
Number of subjects: 6
Study 31809955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29036203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling the lower abdomen with an 8.6°C icepack during the first 2 hours after placental delivery
Number of subjects: 160
Study 29036203 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 160
Study 26783233 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic clinical testing including exercise testing, drug provocation, advanced cardiac imaging, and genetic testing.
Number of subjects: 200
Study 26783233 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator therapy.
Number of subjects: 200
Study 25035340 — intervention group
Group type: EXPERIMENTAL
Intervention: DSE RAM System intervention for risk assessment and workstation modification
Number of subjects: 186
Study 25035340 — intervention group
Group type: EXPERIMENTAL
Intervention: DSE RAM System intervention for promoting behavior change
Number of subjects: 186
Study 25035340 — intervention group
Group type: EXPERIMENTAL
Intervention: DSE RAM System intervention
Number of subjects: 186
Study 22622147 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX plus bevacizumab using a standard triweekly cycle (Q3W)
Number of subjects: 435
Study 22622147 — intervention group
Group type: COMPARATOR
Intervention: XELOX plus bevacizumab using a dose-dense biweekly cycle (Q2W)
Number of subjects: 435
Study 20642467 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgomer CR
Number of subjects: 100
Study 20642467 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji IX
Number of subjects: 100
Study 17546705 — intervention group
Group type: EXPERIMENTAL
Intervention: Offered prenatal screening (n = 1031)
Number of subjects: 1418
Study 17546705 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively screened women (n = 466)
Number of subjects: 1418
Study 17546705 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound screening (n = 285)
Number of subjects: 1418
Study 16110020 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval secondary cytoreduction
Number of subjects: 0
Study 16110020 — intervention group
Group type: COMPARATOR
Intervention: No interval secondary cytoreduction
Number of subjects: 0
Study 16110020 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without interval secondary cytoreduction)
Number of subjects: 0
Study 16110020 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FACT-O score
Number of subjects: 0
Study 11932561 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (GH) treatment, 0.11-0.14 IU.kg-1, daily, s.c.
Number of subjects: 10
Study 11932561 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (GH) treatment
Number of subjects: 10
Study 11932561 — intervention group
Group type: COMPARATOR
Intervention: Control period (standard therapy)
Number of subjects: 10
Study 9806655 — intervention group
Group type: EXPERIMENTAL
Intervention: High grade squamous intraepithelial lesions
Number of subjects: 0
Study 9806655 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive carcinoma
Number of subjects: 0
Study 9806655 — intervention group
Group type: COMPARATOR
Intervention: Low grade squamous intraepithelial lesions
Number of subjects: 0
Study 7632064 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (250 mg/d)
Number of subjects: 195
Study 7632064 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin (1000 mg/d)
Number of subjects: 195
Study 2695448 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week interval schedule of endoscopic injection sclerotherapy
Number of subjects: 40
Study 2695448 — intervention group
Group type: COMPARATOR
Intervention: 2-week interval schedule of endoscopic injection sclerotherapy
Number of subjects: 40
Study 30689860 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced self‐management patient education programme
Number of subjects: 583
Study 30689860 — intervention group
Group type: COMPARATOR
Intervention: Usual care education
Number of subjects: 583
Study 29092885 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (42 mg elemental Fe/d)
Number of subjects: 72
Study 29092885 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (five 25‐min sessions/wk at 75‐85% of maximum heart rate)
Number of subjects: 72
Study 29092885 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation with aerobic training
Number of subjects: 72
Study 29092885 — intervention group
Group type: COMPARATOR
Intervention: Placebo with aerobic training
Number of subjects: 72
Study 27488411 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app-based intervention (Cool Runnings)
Number of subjects: 0
Study 27488411 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification methods within the app
Number of subjects: 0
Study 24768657 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention group (FIG) - GPs not in Catalonia, received all interventions including workshops on rapid tests.
Number of subjects: 281
Study 24768657 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial intervention group (PIG) - Catalan doctors, received all interventions except for the workshop on rapid tests.
Number of subjects: 281
Study 22107037 — intervention group
Group type: EXPERIMENTAL
Intervention: High person-centered messages
Number of subjects: 179
Study 22107037 — intervention group
Group type: EXPERIMENTAL
Intervention: Low person-centered messages
Number of subjects: 179